Targeting HER2 genomic alterations in non-small cell lung cancer

Código QR

Targeting HER2 genomic alterations in non-small cell lung cancer

Oncogenic mutations and amplifications in the erythroblastic oncogene B (ERBB2), or human epidermal growth factor receptor 2 (HER2), have emerged as distinct oncogenic drivers and drug targets in non-small cell lung cancer (NSCLC). Each genomic alteration occurs in 2–4% of NSCLC by next generation s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jie Zeng, Weijie Ma, Richard Benjamin Young, Tianhong Li
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	HER2 ERBB2 Genomic alterations Biomarkers Non-small cell lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3f40bb24885440a89ee50c2dc8b49f30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
por: Diao WY, et al.
Publicado: (2021)

Housekeeping gene as a source of calibrator candidate for HER-2 scoring in frozen tissue breast cancer study based on qPCR
por: RISMAYA RISMAYA, et al.
Publicado: (2017)

Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
por: Jin-xiu Zhong, et al.
Publicado: (2021)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
por: Miladinović Mirjana, et al.
Publicado: (2021)

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases
por: Bernardes,Vanessa Fátima, et al.
Publicado: (2008)

GCC2 as a New Early Diagnostic Biomarker for Non-Small Cell Lung Cancer
por: Hyesun Jeong, et al.
Publicado: (2021)

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
por: Saglican,Yesim, et al.
Publicado: (2015)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato Y, et al.
Publicado: (2021)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021)

<sup>1</sup>H-NMR Plasma Lipoproteins Profile Analysis Reveals Lipid Metabolism Alterations in HER2-Positive Breast Cancer Patients
por: Giuseppe Corona, et al.
Publicado: (2021)

Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer
por: Ying Liu, et al.
Publicado: (2022)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Update Overview of the Role of Angiopoietins in Lung Cancer
por: Dimitris Tsakogiannis, et al.
Publicado: (2021)

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
por: Lu Peng, et al.
Publicado: (2021)

The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers
por: Vokes NI, et al.
Publicado: (2021)

A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
por: I-Han Lee, et al.
Publicado: (2021)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
por: Li J, et al.
Publicado: (2017)

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
por: Damian Mojsak, et al.
Publicado: (2021)

HER-2 positivity is a high risk of recurrence of stage I gastric cancer
por: Seonhoo Kim, et al.
Publicado: (2021)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar I, et al.
Publicado: (2021)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Maja Šutić, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer
por: Yu Q, et al.
Publicado: (2021)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
por: Yalikong A, et al.
Publicado: (2021)

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
por: Jernström S, et al.
Publicado: (2017)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Huanhuan Xu, et al.
Publicado: (2021)

ANTIBODIES TO BENZO[A]PYRENE IN SERUM OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
por: E. G. Polenok, et al.
Publicado: (2012)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

Involvement of endothelial CK2 in the radiation induced perivascular resistant niche (PVRN) and the induction of radioresistance for non-small cell lung cancer (NSCLC) cells
por: Li,Qianwen, et al.
Publicado: (2019)

Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
por: Isobe H, et al.
Publicado: (2017)

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy
por: Hui Yang, et al.
Publicado: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Circular RNA circ_0000517 Facilitates The Growth and Metastasis of Non-Small Cell Lung Cancer by Sponging miR-326/miR-330-5p
por: Qiyan Tan, et al.
Publicado: (2021)

A Cytoplasm-Enriched circRNA circ-MYBL2 is Downregulated in Non-Small Cell Lung Cancer and Sponges Oncogenic miR-28 to Regulate Cancer Cell Proliferation and Apoptosis [Retraction]
por: Mao Y, et al.
Publicado: (2021)

Biomarkers for screening of lung cancer and pre-neoplastic lesions in a high risk Chilean population
por: Adonis,Marta I, et al.
Publicado: (2014)

Research on the application of uniportal video-assisted thoracoscopic segmental resection of the lung in elderly patients with non-small cell lung cancer aged over 65 years
por: Hongya Xie, et al.
Publicado: (2021)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)